Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Probiotix Health's enterprise value is €17.91 Mil.
Probiotix Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.36 Mil. Therefore, Probiotix Health's EV-to-EBITDA for today is -13.20.
The historical rank and industry rank for Probiotix Health's EV-to-EBITDA or its related term are showing as below:
FRA:X90'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.5 Med: -6.88 Max: 341.84
Current: -12.97
During the past 7 years, the highest EV-to-EBITDA of Probiotix Health was 341.84. The lowest was -19.50. And the median was -6.88.
FRA:X90's EV-to-EBITDA is ranked worse than 100% of 408
companies
in the Biotechnology industry
Industry Median: 14.13
vs FRA:X90: -12.97
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Probiotix Health (FRA:X90) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Probiotix Health's PE Ratio (TTM) for today is calculated as:
Probiotix Health's share price for today is €0.089.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Probiotix Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.009.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Probiotix Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:X90 vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Probiotix Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Probiotix Health EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Probiotix Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Probiotix Health's EV-to-EBITDA falls into.
Probiotix Health's current Enterprise Value is €17.91 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Probiotix Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Probiotix Health (FRA:X90) has a EV-to-EBITDA of -13.20 as of Aug. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Probiotix Health. According to the industry distribution chart, Probiotix Health ranks #999999 out of 408 companies in the Biotechnology industry.
Is Probiotix Health's EV-to-EBITDA too high?
Probiotix Health's current EV-to-EBITDA is -13.20. Based on the distribution chart, Probiotix Health ranks #999999 out of 408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Probiotix Health has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Probiotix Health's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Probiotix Health ranks #999999 out of 408 companies for EV-to-EBITDA. This places Probiotix Health in the lower half of its industry. The industry median EV-to-EBITDA is 14.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.13, based on 408 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Probiotix Health. For the Biotechnology industry, the median EV-to-EBITDA is 14.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Probiotix Health's current EV-to-EBITDA is -13.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Probiotix Health stock overvalued right now?
Probiotix Health (FRA:X90) has a current EV-to-EBITDA of -13.20. The stock's GF Value™ is €0.08, compared to a current price of €0.09 — trading 11.3% above its estimated fair value. The current EV-to-EBITDA is -13.20. Probiotix Health's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Probiotix Health (FRA:X90), the current EV-to-EBITDA is -13.20 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Probiotix Health (FRA:X90) Overvalued in 2026?
Based on GuruFocus' analysis, Probiotix Health stock appears to be overvalued.
The current stock price of €0.09 is trading 11.3% above its estimated GF Value™ of €0.08.
Key valuation signals for FRA:X90:
EV-to-EBITDA: -13.20
GF Value™: €0.08 vs. price of €0.09 (11.3% above fair value)
No single metric tells the full story. See the FRA:X90 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Probiotix Health PLC is a life sciences company that develops probiotics to tackle cardiovascular disease and other lifestyle conditions that are affecting growing numbers of people across the world. The company has one class of business, in three geographical areas, being that of identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry. Its geographical segments include the United Kingdom, the United States, and the Rest of the World. It generates the majority of its revenue from the United States.
27GF Score
Get the complete analysis for FRA:X90
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:X90 has been successfully added to your 
